Skip to main content
Fig. 2 | Basic and Clinical Andrology

Fig. 2

From: Contribution of serum anti-Müllerian hormone in the management of azoospermia and the prediction of testicular sperm retrieval outcomes: a study of 155 adult men

Fig. 2

a Anti-Müllerian hormone (AMH) serum levels and b AMH to total testosterone (AMH/T) values in azoospermia according to etiology. For AMH serum levels:* (p=0.02) unexplained nonobstructive azoospermia (NOA) versus obstructive azoospermia (OA), (p=0.001) cryptorchidism-related spermatogenic failure (Cryptorchidism) NOA versus OA, # (p=0.04) cytotoxic spermatogenic failure (Cytotoxic) NOA versus OA, $ (p<0.0001) genetic spermatogenic failure (Genetic) NOA versus OA, $$ (p<0.0001) Genetic versus unexplained NOA. $$$ (p=0.04) Cryptorchidism NOA versus Genetic NOA. For AMH/T: (p<0.0001) Genetic NOA versus OA, (p<0.0001) Genetic versus unexplained NOA. (p=0.005) Cryptorchidism NOA versus Genetic NOA. Statistical analysis was performed by the Kruskal-Wallis test with the two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli post hoc tests. c and d Anti-Müllerian hormone (AMH) serum levels and AMH to testosterone ratio values in different categories of genetic NOA. (p=0.0001) Klinefelter syndrome NOA versus Y-chromosome microdeletions NOA. ♰♰ (p=0.0005) Klinefelter syndrome NOA versus Y-chromosome microdeletions NOA. Statistical analysis was performed by the two-tailed Mann Whitney U test. Horizontal bars show median values and interquartile ranges. Dashed lines represent the reference values range for the serum level of AMH [14–78.5 pmol/l]. AMH/Testosterone AMH-to-total testosterone ratio, NOA Nonobstructive azoospermia, OA Obstructiveazoospermia

Back to article page